The psychopharmacology department at Maastricht University focuses on the cognitive, behavioral, and biological effects of various substances, ranging from pharmaceutical to recreational drugs
Most street cannabis contains large quantities of THC, the chemical in cannabis that gets people ‘high’, but there is increasing use of medicinal products that also contain CBD, a non-intoxicating cannabinoid with promising therapeutically potential. It has often been proposed that administering CBD may reduce some of the impairment caused by THC. To test this,… Continue reading Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.
Pint of Science is coming to the Netherlands this year, and we will be sharing some of our research! If you are in the Maastricht area on May 20th, come to Cafe Charlemagne to hear about "the good, the bad, and the intoxicated". For full event info, check out the website.
New study from our group assessed cognitive and subjective effects of a synthetic cannabinoid, JWH-018. Read coverage of the publication from Live Science.
March 25, 2019. Researchers from IMIM (Barcelona) and our department employed the quantification of monoamine neurotransmitters and steroid hormones in brain tissue and blood of rats to predict the pharmacological similarity of NPS to classical drugs of abuse. The metabolomics approach in animals improves the speed of NPS classification.
After many years of animal research, in which we found that inhibition of the enzyme phosphodiesterase type 4 (PDE4) improved memory in animals, we now find first evidence that this mechanism also works in humans. In this study, we tested how many words older participants (aged between 60 and 85 years old) could remember from… Continue reading Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study